Blog
RSS FeedPosted by Michael Wonder on 25 Nov 2018
Canada has found the key to lowering drug prices, but it won't be used any time soon
24 November 2018 - Health Canada has quietly delayed implementation date for controversial drug rules. ...
Posted by Michael Wonder on 24 Nov 2018
Indivior announces Health Canada approval of Sublocade (buprenorphine extended release) injection for patients with moderate to severe opioid use disorder
23 November 2018 - Sublocade is the first and only once-monthly injectable buprenorphine formulation approved in Canada for the management of ...
Posted by Michael Wonder on 15 Nov 2018
Inclusion of data on treatment discontinuation in the Tasigna product monograph approved by Health Canada for CML patients who achieve a sustained molecular response
13 November 2018 - Approval is based on two studies showing more than half of patients remained in remission after stopping ...
Posted by Michael Wonder on 12 Nov 2018
Oversight gap at private infusion clinics poses health risk, Ontario documents say
12 November 2018 - The lack of formal oversight at private clinics where medications are administered intravenously could pose risks ...
Posted by Michael Wonder on 02 Nov 2018
Servier receives Health Canada approval of Folotyn for the treatment of relapsed or refractory peripheral T-cell lymphoma
1 November 2018 - Servier Canada announced that Health Canada granted a Notice of Compliance with conditions for Folotyn (pralatrexate) for ...
Posted by Michael Wonder on 01 Nov 2018
Novartis receives Health Canada approval for the combination therapy of Tafinlar (dabrafenib) plus Mekinist (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma
1 November 2018 - First approval in Canada of an adjuvant treatment for melanoma (BRAF V600 mutated). ...
Posted by Michael Wonder on 26 Oct 2018
Bayer receives approval for haemophilia A treatment Jivi
24 October 2018 - Extended half-life product that offers a reduction in dosing frequency and improved bleeding protection. ...
Posted by Michael Wonder on 18 Oct 2018
Health Canada has approved Invokana (canagliflozin) for reduction of major adverse cardiovascular events, the first SGLT2 inhibitor in Canada to receive this indication
17 October 2018 - Invokana has been shown to reduce the combined risk of cardiovascular death, non-fatal myocardial infarction and ...
Posted by Michael Wonder on 17 Oct 2018
Health Canada approves Xermelo (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea
16 October 2018 - Xermelo is a first-in-class treatment option for patients whose refractory carcinoid syndrome diarrhoea is inadequately controlled with ...
Posted by Michael Wonder on 09 Oct 2018
Health Canada approves new indications for Xeljanz in ulcerative colitis & psoriatic arthritis
9 October 2018 - Xeljanz, an oral therapy, is the first and only Janus kinase inhibitor approved by Health Canada for ...
Posted by Michael Wonder on 06 Oct 2018
AbbVie receives Health Canada approval of Orilissa (elagolix) for the treatment of moderate to severe pain associated with endometriosis
5 October 2018 - The approval of Orilissa is supported by data from two replicate Phase 3 studies, which evaluated nearly ...
Posted by Michael Wonder on 05 Oct 2018
Health Canada approves Radicava (edaravone) for the treatment of ALS
5 October 2018 - Mitsubishi Tanabe Pharma Corporation announced today that Edaravone (US name: Radicava; Japan name: Radicut bag for ...
Posted by Michael Wonder on 05 Oct 2018
Akcea and Ionis announce approval of Tegsedi (inotersen injection) in Canada
4 October 2018 - First and only treatment of its kind for Canadians with hereditary transthyretin-mediated amyloidosis with polyneuropathy – a ...
Posted by Michael Wonder on 02 Oct 2018
Health Canada approves Tresiba for children with Type 1 diabetes
1 October 2018 - Rates of Type 1 diabetes among children and youth on the rise globally. ...
Posted by Michael Wonder on 26 Sep 2018
AbbVie receives approval from Health Canada for the combination of Venclexta with rituximab as a treatment for patients with chronic lymphocytic leukaemia
25 September 2018 - In the MURANO Phase 3 clinical trial, the Venclexta (venetoclax) plus rituximab combination showed a significant improvement ...